Kiniksa Pharmaceuticals (NASDAQ:KNSA) Issues Earnings Results, Beats Expectations By $0.03 EPS
Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its quarterly earnings results on Monday. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.03, Fidelity Earnings reports.
KNSA opened at $10.69 on Thursday. The business has a fifty day moving average price of $12.99. The company has a market capitalization of $601.16 million, a P/E ratio of -3.06 and a beta of -1.56. Kiniksa Pharmaceuticals has a 12-month low of $10.10 and a 12-month high of $32.88.
A number of analysts recently commented on KNSA shares. ValuEngine raised Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. JMP Securities dropped their price target on Kiniksa Pharmaceuticals to $35.00 and set a “market outperform” rating for the company in a research note on Wednesday. They noted that the move was a valuation call. Zacks Investment Research raised Kiniksa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 4th. Finally, Wedbush reaffirmed a “buy” rating on shares of Kiniksa Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $29.25.
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Story: What are momentum indicators and what do they show?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.